Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free IKT Stock Alerts

Inhibikase Therapeutics (IKT) Financials

Inhibikase Therapeutics logo
$2.04 0.00 (0.00%)
Closing price 07/10/2026 04:00 PM Eastern
Extended Trading
$1.99 -0.05 (-2.60%)
As of 07/10/2026 04:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Inhibikase Therapeutics

Annual Income Statements for Inhibikase Therapeutics

This table shows Inhibikase Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -2.85 -15 -18 -19 -28 -48
Consolidated Net Income / (Loss)		 -2.85 -15 -18 -19 -28 -48
Net Income / (Loss) Continuing Operations		 -2.85 -15 -18 -19 -28 -48
Total Pre-Tax Income 		-2.85 -15 -18 -19 -28 -48
Total Operating Income		 -2.82 -15 -18 -20 -29 -52
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 2.82 15 18 20 29 52
Selling, General & Admin Expense		 2.62 6.51 6.22 6.73 11 24
Research & Development Expense		 0.89 11 12 14 17 30
Other Operating Expenses / (Income)		 -0.70 -3.10 -0.12 -0.26 - -1.37
Total Other Income / (Expense), net		 -0.03 -0.02 0.07 1.06 1.03 3.72
Interest Expense		 0.03 0.02 -0.07 -1.06 -1.07 -3.72
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - 0.00 -0.10 0.10 - -0.06
Basic Earnings per Share		 ($0.35) ($0.81) ($4.28) ($3.16) ($1.16) ($0.49)
Weighted Average Basic Shares Outstanding		 8.21M 18.21M 4.22M 6.03M 23.71M 98.31M
Diluted Earnings per Share		 ($0.35) ($0.81) ($4.28) ($3.16) ($1.16) ($0.49)
Weighted Average Diluted Shares Outstanding		 8.21M 18.21M 4.22M 6.03M 23.71M 98.31M
Weighted Average Basic & Diluted Shares Outstanding		 8.21M 18.21M 28.98M 6.48M 74.34M 132.03M

Quarterly Income Statements for Inhibikase Therapeutics

This table shows Inhibikase Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -4.60 -4.18 -4.65 -4.96 -5.78 -12 -14 -9.92 -12 -13 -16
Consolidated Net Income / (Loss)		 -4.60 -4.18 -4.65 -4.96 -5.78 -12 -14 -9.92 -12 -13 -16
Net Income / (Loss) Continuing Operations		 -4.59 -4.01 -4.65 -4.96 -5.78 -12 -14 -9.92 -12 -13 -16
Total Pre-Tax Income 		-4.59 -4.01 -4.65 -4.96 -5.78 -12 -14 -9.92 -12 -13 -16
Total Operating Income		 -4.77 -4.40 -4.78 -5.05 -5.83 -13 -15 -11 -13 -14 -18
Total Gross Profit		 0.08 -0.20 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.08 -0.20 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 4.85 4.21 4.78 5.05 5.83 13 15 11 13 14 18
Selling, General & Admin Expense		 1.62 1.40 2.03 1.97 1.64 5.74 5.25 5.92 5.61 6.77 7.38
Research & Development Expense		 3.23 3.00 2.75 3.08 4.19 7.19 11 5.27 7.65 6.36 11
Other Operating Expenses / (Income)		 - - 0.00 0.00 0.00 - -1.16 -0.36 -0.49 0.64 -0.37
Total Other Income / (Expense), net		 0.18 0.39 0.13 0.09 0.05 0.80 0.92 0.92 0.84 1.00 1.46
Interest Expense		 -0.17 -0.23 -0.13 -0.09 -0.05 -0.80 -0.92 -0.92 -0.84 -1.04 -1.46
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - - - -0.00 -0.00 0.04 -0.04 0.00 0.00 - 0.05
Basic Earnings per Share		 ($0.75) ($0.69) ($0.73) ($0.66) ($0.65) ($0.51) ($0.15) ($0.11) ($0.13) ($0.10) ($0.10)
Weighted Average Basic Shares Outstanding		 6.16M 6.03M 6.34M 7.54M 8.88M 23.71M 89.54M 90.01M 90.05M 98.31M 172.31M
Diluted Earnings per Share		 ($0.75) ($0.69) ($0.73) ($0.66) ($0.65) ($0.51) ($0.15) ($0.11) ($0.13) ($0.10) ($0.10)
Weighted Average Diluted Shares Outstanding		 6.16M 6.03M 6.34M 7.54M 8.88M 23.71M 89.54M 90.01M 90.05M 98.31M 172.31M
Weighted Average Basic & Diluted Shares Outstanding		 6.17M 6.48M 6.48M 7.46M 67.19M 74.34M 74.34M 74.52M 75.18M 132.03M 132.03M

Annual Cash Flow Statements for Inhibikase Therapeutics

This table details how cash moves in and out of Inhibikase Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 14 27 -34 1.98 47 83
Net Cash From Operating Activities		 -1.13 -14 -17 -18 -19 -28
Net Cash From Continuing Operating Activities		 -1.13 -14 -17 -18 -19 -28
Net Income / (Loss) Continuing Operations		 -2.85 -15 -18 -19 -28 -48
Consolidated Net Income / (Loss)		 -2.85 -15 -18 -19 -28 -48
Depreciation Expense		 - 0.00 0.01 0.18 0.03 0.06
Non-Cash Adjustments To Reconcile Net Income		 2.18 2.92 -0.45 1.54 8.40 20
Changes in Operating Assets and Liabilities, net		 -0.46 -2.43 1.14 -0.77 -0.05 0.50
Net Cash From Investing Activities		 0.00 0.00 -16 12 -37 2.05
Net Cash From Continuing Investing Activities		 0.00 0.00 -16 12 -37 2.05
Purchase of Property, Plant & Equipment		 - 0.00 -0.24 -0.01 0.00 -0.01
Acquisitions		 - - - - 0.00 -0.44
Purchase of Investments		 - 0.00 -21 -29 -60 -39
Sale and/or Maturity of Investments		 - 0.00 4.96 41 23 42
Net Cash From Financing Activities		 15 41 -0.20 8.41 103 108
Net Cash From Continuing Financing Activities		 15 41 -0.20 8.41 103 108
Issuance of Common Equity		 15 41 0.00 8.54 103 108
Other Financing Activities, net		 0.00 0.00 0.04 -0.14 0.00 0.85

Quarterly Cash Flow Statements for Inhibikase Therapeutics

This table details how cash moves in and out of Inhibikase Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 13 -5.70 -6.81 0.73 -2.17 56 17 4.30 -39 101 -90
Net Cash From Operating Activities		 -4.11 -3.44 -3.87 -5.05 -4.88 -5.35 -4.10 -5.57 -11 -7.52 -12
Net Cash From Continuing Operating Activities		 -4.11 -3.44 -3.87 -5.05 -4.88 -5.35 -4.10 -5.57 -11 -7.52 -12
Net Income / (Loss) Continuing Operations		 -4.60 -4.18 -4.65 -4.96 -5.78 -12 -14 -9.92 -12 -13 -16
Consolidated Net Income / (Loss)		 -4.60 -4.18 -4.65 -4.96 -5.78 -12 -14 -9.92 -12 -13 -16
Depreciation Expense		 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02 - 0.00
Non-Cash Adjustments To Reconcile Net Income		 0.25 0.29 0.09 -0.04 0.37 7.97 9.46 5.35 2.92 3.38 5.23
Changes in Operating Assets and Liabilities, net		 0.23 0.44 0.68 -0.06 0.52 -1.19 0.10 -1.04 -1.60 1.84 -0.91
Net Cash From Investing Activities		 17 -2.12 -3.31 2.54 2.53 -39 21 9.84 -29 -0.10 -80
Net Cash From Continuing Investing Activities		 17 -2.12 -3.31 2.54 2.53 -39 21 9.84 -29 -0.10 -80
Purchase of Property, Plant & Equipment		 - - 0.00 - - - -0.01 - - - 0.00
Acquisitions		 - - 0.00 - - - -0.44 - - - 0.00
Purchase of Investments		 -1.95 -8.80 -8.43 -0.78 -1.13 -50 0.00 - -39 -0.10 -91
Sale and/or Maturity of Investments		 19 6.68 5.12 3.32 3.66 11 22 9.84 10 - 10
Net Cash From Financing Activities		 0.00 -0.14 0.37 3.24 0.18 100 0.00 0.03 -0.13 109 2.90
Net Cash From Continuing Financing Activities		 0.00 -0.14 0.37 3.24 0.18 100 0.00 0.03 -0.13 109 2.90
Issuance of Common Equity		 0.00 0.00 0.40 3.21 0.18 100 0.00 0.00 - 108 2.90
Other Financing Activities, net		 - - -0.03 0.03 - - 0.00 0.03 -0.13 0.95 0.00

Annual Balance Sheets for Inhibikase Therapeutics

This table presents Inhibikase Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 15 42 25 15 99 181
Total Current Assets		 15 42 24 14 98 180
Cash & Equivalents		 14 41 7.19 9.17 56 139
Short-Term Investments		 - 0.00 16 4.09 41 40
Prepaid Expenses		 0.83 1.61 1.28 0.96 0.91 1.35
Other Current Assets		 - - - - - 0.00
Plant, Property, & Equipment, net		 0.00 0.00 0.24 0.07 0.05 0.00
Total Noncurrent Assets		 0.00 0.00 0.33 0.22 0.10 1.10
Other Noncurrent Operating Assets		 - 0.00 0.33 0.22 0.10 1.10
Total Liabilities & Shareholders' Equity		 15 42 25 15 99 181
Total Liabilities		 5.00 4.05 3.90 3.53 3.73 8.30
Total Current Liabilities		 4.72 4.05 3.70 3.44 3.73 8.30
Short-Term Debt		 0.04 0.00 0.15 0.15 0.11 0.00
Accounts Payable		 1.72 1.09 1.15 0.65 0.94 1.16
Accrued Expenses		 0.63 2.72 2.40 2.26 2.68 4.08
Other Current Liabilities		 - 0.25 0.00 0.38 0.00 3.06
Total Noncurrent Liabilities		 0.28 0.00 0.21 0.09 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 40 38 21 11 95 173
Total Preferred & Common Equity		 9.78 38 21 11 95 173
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 40 38 21 11 95 173
Common Stock		 25 68 69 78 189 316
Retained Earnings		 15 -30 -48 -67 -94 -143
Accumulated Other Comprehensive Income / (Loss)		 - 0.00 0.10 0.00 -0.04 0.02

Quarterly Balance Sheets for Inhibikase Therapeutics

This table presents Inhibikase Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 18 11 8.83 4.38 94 89 80 173
Total Current Assets		 18 11 8.60 4.19 94 89 79 172
Cash & Equivalents		 15 2.35 3.09 0.91 73 78 38 50
Short-Term Investments		 1.97 7.40 4.85 2.33 20 9.92 39 121
Prepaid Expenses		 0.72 1.06 0.66 0.39 0.98 0.82 0.83 1.81
Other Current Assets		 - - - 0.55 0.00 0.31 0.39 0.00
Plant, Property, & Equipment, net		 0.08 0.07 0.06 0.05 0.05 0.02 0.00 0.00
Total Noncurrent Assets		 0.25 0.19 0.16 0.13 0.07 0.03 1.06 1.16
Other Noncurrent Operating Assets		 0.25 0.19 0.16 0.13 0.07 0.03 1.06 1.16
Total Liabilities & Shareholders' Equity		 18 11 8.83 4.38 94 89 80 173
Total Liabilities		 2.86 4.29 3.73 4.91 8.55 8.80 6.70 5.71
Total Current Liabilities		 2.74 4.23 3.70 4.91 8.55 8.80 6.70 5.71
Short-Term Debt		 0.15 0.15 0.15 0.15 0.07 0.04 0.00 0.00
Accounts Payable		 0.73 1.29 1.34 2.53 1.69 2.70 0.62 1.59
Accrued Expenses		 1.86 2.51 2.03 2.16 3.51 3.15 3.66 4.12
Other Current Liabilities		 - 0.28 0.18 0.07 3.27 2.91 2.42 0.00
Total Noncurrent Liabilities		 0.12 0.06 0.03 0.00 0.00 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 15 6.78 5.10 -0.53 86 80 73 168
Total Preferred & Common Equity		 15 6.78 5.10 -0.53 86 80 73 168
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 15 6.78 5.10 -0.53 86 80 73 168
Common Stock		 78 78 82 82 194 198 203 327
Retained Earnings		 -63 -72 -77 -82 -108 -118 -130 -159
Accumulated Other Comprehensive Income / (Loss)		 -0.00 -0.00 -0.00 0.00 -0.00 -0.00 -0.00 -0.03

Annual Metrics And Ratios for Inhibikase Therapeutics

This table displays calculated financial ratios and metrics derived from Inhibikase Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 25,155,198.00 25,227,051.00 6,174,280.00 - 75,175,306.00
DEI Adjusted Shares Outstanding		 0.00 4,192,533.00 4,204,509.00 6,174,280.00 - 75,175,306.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -3.53 -4.27 -3.10 - -0.64
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -423.90% -22.73% -9.88% -43.44% -81.51%
EBIT Growth		 0.00% -423.90% -22.77% -10.82% -42.31% -81.56%
NOPAT Growth		 0.00% -423.90% -22.77% -10.82% -42.31% -81.80%
Net Income Growth		 0.00% -419.19% -22.10% -5.40% -44.62% -75.36%
EPS Growth		 0.00% -131.43% -22.10% 26.17% 63.29% 57.76%
Operating Cash Flow Growth		 0.00% -1,165.95% -21.36% -4.23% -5.88% -45.11%
Free Cash Flow Firm Growth		 0.00% 0.00% -12.73% -2.48% -42.27% -69.86%
Invested Capital Growth		 0.00% 39.36% 28.75% -22.27% -26.20% -128.32%
Revenue Q/Q Growth		 0.00% 0.00% -100.00% -100.00% 100.00% 0.00%
EBITDA Q/Q Growth		 0.00% -35.15% 3.78% -0.34% -42.55% -1.67%
EBIT Q/Q Growth		 0.00% -35.15% 3.75% -0.34% -42.49% -1.66%
NOPAT Q/Q Growth		 0.00% -35.15% 3.75% -0.34% -42.49% -1.66%
Net Income Q/Q Growth		 0.00% -35.00% 4.05% 0.53% -40.66% -1.26%
EPS Q/Q Growth		 0.00% -84.09% 4.05% -1.61% 47.27% 7.55%
Operating Cash Flow Q/Q Growth		 0.00% -28.25% 3.02% 0.63% -11.04% -8.47%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 1.73% -1.46% -62.88% 5.45%
Invested Capital Q/Q Growth		 0.00% -62.63% -62.46% -31.76% 29.27% -32.47%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 101.04% 100.13% 99.59% 94.72% 96.26% 92.85%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -7.15% -37.79% -60.74% -118.88% -52.00% -36.05%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -7.15% -37.79% -60.74% -118.88% -52.00% -36.05%
Return on Equity Simple (ROE_SIMPLE)		 -29.11% -38.49% -85.83% -173.34% -29.01% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.97 -10 -13 -14 -20 -36
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.00% -10.54% -16.91% -27.81% -13.60% -8.60%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -125.36% -21.07% -21.04%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -2.82 -15 -18 -20 -29 -52
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -2.82 -15 -18 -20 -29 -52
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 1.42 0.96 0.60 0.71 2.30 0.89
Price to Tangible Book Value (P/TBV)		 1.42 0.96 0.60 0.71 2.30 0.89
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.01 0.00 0.02 0.02 0.00 0.00
Long-Term Debt to Equity		 0.01 0.00 0.01 0.01 0.00 0.00
Financial Leverage		 -1.10 -1.08 -1.07 -1.12 -1.04 -1.03
Leverage Ratio		 0.37 0.73 1.13 1.23 1.07 1.04
Compound Leverage Factor		 0.37 0.73 1.13 1.17 1.03 0.97
Debt to Total Capital		 0.79% 0.00% 1.64% 2.14% 0.12% 0.00%
Short-Term Debt to Total Capital		 0.11% 0.00% 0.68% 1.34% 0.12% 0.00%
Long-Term Debt to Total Capital		 0.69% 0.00% 0.96% 0.80% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 99.21% 100.00% 98.36% 97.86% 99.88% 100.00%
Debt to EBITDA		 -0.11 0.00 -0.02 -0.01 0.00 0.00
Net Debt to EBITDA		 4.84 0.00 1.25 0.65 3.41 0.00
Long-Term Debt to EBITDA		 -0.10 0.00 -0.01 0.00 0.00 0.00
Debt to NOPAT		 -0.16 0.00 -0.03 -0.02 -0.01 0.00
Net Debt to NOPAT		 6.91 0.00 1.79 0.93 4.87 0.00
Long-Term Debt to NOPAT		 -0.14 0.00 -0.02 -0.01 0.00 0.00
Altman Z-Score		 8.39 4.43 -2.15 -8.80 33.95 10.23
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 3.13 10.47 6.59 4.13 26.37 21.70
Quick Ratio		 2.96 10.08 6.25 3.85 26.13 21.54
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -12 -13 -14 -19 -33
Operating Cash Flow to CapEx		 0.00% 0.00% -7,132.89% -127,019.55% 0.00% -207,377.15%
Free Cash Flow to Firm to Interest Expense		 0.00 -594.88 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -38.41 -717.62 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -38.41 -717.62 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -3.85 -2.33 -1.66 -2.03 -2.57 -5.86
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 1.52 0.67 -0.37 -0.53 -3.29
Enterprise Value (EV)		 43 -3.77 -10 -5.17 121 -25
Market Capitalization		 56 37 13 7.84 218 154
Book Value per Share		 $4.85 $1.53 $0.83 $1.78 $1.41 $2.30
Tangible Book Value per Share		 $4.85 $1.53 $0.83 $1.78 $1.41 $2.30
Total Capital		 40 38 21 11 95 173
Total Debt		 0.32 0.00 0.35 0.24 0.11 0.00
Total Long-Term Debt		 0.28 0.00 0.21 0.09 0.00 0.00
Net Debt		 -14 -41 -23 -13 -97 -179
Capital Expenditures (CapEx)		 0.00 0.00 0.24 0.01 0.00 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.85 -2.33 -2.23 -2.33 -2.72 -6.96
Debt-free Net Working Capital (DFNWC)		 10 38 21 11 95 172
Net Working Capital (NWC)		 10 38 21 11 95 172
Net Nonoperating Expense (NNE)		 0.87 4.45 5.36 4.97 7.51 12
Net Nonoperating Obligations (NNO)		 -44 -41 -23 -13 -97 -179
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.01 0.18 0.03 0.06
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($4.86) ($4.32) ($3.57) ($1.16) ($0.49)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 4.20M 4.20M 5.33M 23.71M 98.31M
Adjusted Diluted Earnings per Share		 $0.00 ($4.86) ($4.32) ($3.57) ($1.16) ($0.49)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 4.20M 4.20M 5.33M 23.71M 98.31M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($4.86) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 3.03M 4.83M 6.48M 74.34M 132.03M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.97 -10 -13 -14 -20 -36
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 -95.86 -741.16 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -67.10 -518.81 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -95.86 -741.16 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -67.10 -518.81 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Inhibikase Therapeutics

This table displays calculated financial ratios and metrics derived from Inhibikase Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 5,348,326.00 6,174,280.00 6,476,844.00 6,476,844.00 7,464,070.00 - 74,341,540.00 74,341,540.00 74,516,635.00 75,175,306.00 132,032,636.00
DEI Adjusted Shares Outstanding		 5,348,326.00 6,174,280.00 6,476,844.00 6,476,844.00 7,464,070.00 - 74,341,540.00 74,341,540.00 74,516,635.00 75,175,306.00 132,032,636.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.86 -0.68 -0.72 -0.77 -0.77 - -0.18 -0.13 -0.16 -0.17 -0.12
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% -325.75% 0.00% -100.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -5.53% -1.55% -1.46% 18.79% -22.27% -193.89% -205.23% -114.28% -118.95% -6.60% -22.33%
EBIT Growth		 -5.63% -1.58% -1.49% 20.71% -22.24% -193.60% -205.08% -114.48% -119.11% -6.55% -22.22%
NOPAT Growth		 -5.67% -1.58% -1.43% 18.57% -22.20% -193.60% -205.25% -114.48% -119.11% -6.55% -22.22%
Net Income Growth		 -2.24% 2.36% -3.84% 14.16% -25.74% -190.40% -194.19% -99.93% -106.48% -4.96% -19.75%
EPS Growth		 29.25% 30.30% 25.51% 29.79% 13.33% 26.09% 79.45% 83.33% 80.00% 80.39% 33.33%
Operating Cash Flow Growth		 25.43% 3.20% 35.25% -10.71% -18.90% -55.28% -6.12% -10.29% -117.02% -40.60% -193.89%
Free Cash Flow Firm Growth		 21.07% 26.81% 88.74% 65.26% 29.26% -214.05% -753.98% -30.92% -308.40% 25.45% -205.26%
Invested Capital Growth		 -50.76% -22.27% -3,730.67% -127.30% -135.10% -26.20% -166.89% -184.15% -21.90% -128.32% 62.73%
Revenue Q/Q Growth		 -31.65% -346.30% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 23.35% 7.64% -8.68% -5.56% -15.40% -122.00% -12.87% 25.71% -17.92% -8.09% -29.52%
EBIT Q/Q Growth		 25.16% 7.63% -8.66% -5.55% -15.38% -121.86% -12.91% 25.61% -17.87% -7.89% -29.52%
NOPAT Q/Q Growth		 23.11% 7.66% -8.60% -5.61% -15.38% -121.86% -12.91% 25.80% -17.87% -7.89% -29.52%
Net Income Q/Q Growth		 20.47% 9.08% -11.29% -6.67% -16.50% -109.98% -12.74% 27.51% -20.32% -6.74% -28.63%
EPS Q/Q Growth		 20.21% 8.00% -5.80% 9.59% 1.52% 21.54% 70.59% 26.67% -18.18% 23.08% 0.00%
Operating Cash Flow Q/Q Growth		 10.08% 16.14% -12.33% -30.70% 3.43% -9.52% 23.24% -35.84% -90.03% 29.05% -60.45%
Free Cash Flow Firm Q/Q Growth		 52.06% 3.78% 75.79% -211.09% 2.38% -327.18% 34.17% 52.31% -204.53% 22.03% -169.57%
Invested Capital Q/Q Growth		 -31.63% -31.76% -35.86% 3.54% -36.15% 29.27% -187.32% -2.70% 41.59% -32.47% 53.10%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -5,983.14% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -5,993.38% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -5,991.41% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -5,775.11% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.03% 104.14% 99.94% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.72% 100.00%
Interest Burden Percent		 96.36% 91.11% 97.23% 98.20% 99.15% 93.84% 93.70% 91.54% 93.44% 92.71% 91.81%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -95.28% -118.88% -119.64% -149.69% -270.10% -52.00% -79.02% -97.49% -131.71% -36.05% -40.23%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -38.67% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -37.28% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -95.28% -118.88% -119.64% -149.69% -270.10% -52.00% -79.02% -97.49% -131.71% -36.05% -40.23%
Return on Equity Simple (ROE_SIMPLE)		 -127.38% 0.00% -283.34% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.34 -3.08 -3.35 -3.54 -4.08 -9.05 -10 -7.58 -8.94 -9.64 -12
NOPAT Margin		 -4,195.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -5.88% -6.14% -7.45% -10.03% -17.28% -5.58% -6.74% -4.89% -7.44% -2.24% -2.95%
Return On Investment Capital (ROIC_SIMPLE)		 - -27.48% -47.92% -67.03% 1,058.49% -9.53% -11.91% -9.47% -12.26% -5.58% -7.45%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 2,039.61% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 4,053.78% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 6,093.38% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -4.77 -4.40 -4.79 -5.05 -5.83 -13 -15 -11 -13 -14 -18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.76 -4.40 -4.78 -5.04 -5.82 -13 -15 -11 -13 -14 -18
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.50 0.71 2.06 1.54 0.00 2.30 1.90 1.81 1.66 0.89 1.32
Price to Tangible Book Value (P/TBV)		 0.50 0.71 2.06 1.54 0.00 2.30 1.90 1.81 1.66 0.89 1.32
Price to Revenue (P/Rev)		 49.58 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.02 0.02 0.03 0.03 -0.27 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.06 -1.12 -1.09 -1.16 -1.36 -1.04 -1.11 -1.12 -1.11 -1.03 -1.04
Leverage Ratio		 1.16 1.23 1.22 1.27 1.54 1.07 1.14 1.15 1.16 1.04 1.06
Compound Leverage Factor		 1.11 1.12 1.19 1.25 1.52 1.00 1.07 1.05 1.08 0.97 0.97
Debt to Total Capital		 1.77% 2.14% 3.00% 3.37% -37.68% 0.12% 0.09% 0.05% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.97% 1.34% 2.16% 2.89% -37.68% 0.12% 0.09% 0.05% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.79% 0.80% 0.83% 0.49% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 98.23% 97.86% 97.00% 96.63% 137.68% 99.88% 99.91% 99.95% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.01 -0.01 -0.01 -0.01 -0.01 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.83 0.65 0.48 0.41 0.15 3.41 2.43 1.99 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.02 -0.02 -0.01 -0.01 -0.01 -0.01 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 1.18 0.93 0.68 0.58 0.22 4.87 3.46 2.83 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -0.01 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -3.23 -5.23 -7.81 -12.11 -29.77 34.47 10.40 8.70 9.08 10.92 22.83
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.40 4.13 2.55 2.32 0.85 26.37 11.01 10.09 11.73 21.70 30.14
Quick Ratio		 6.14 3.85 2.30 2.14 0.66 26.13 10.90 9.96 11.55 21.54 29.83
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -2.82 -2.71 -0.66 -2.04 -1.99 -8.52 -5.61 -2.67 -8.14 -6.35 -17
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -30,625.64% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.93 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.54 -2.03 -2.76 -2.67 -3.63 -2.57 -7.37 -7.57 -4.42 -5.86 -2.75
Invested Capital Turnover		 -0.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -0.52 -0.37 -2.69 -1.49 -2.09 -0.53 -4.61 -4.91 -0.79 -3.29 4.63
Enterprise Value (EV)		 -9.13 -5.17 4.45 0.07 6.60 121 70 57 43 -25 51
Market Capitalization		 7.43 7.84 14 7.84 9.70 218 163 145 121 154 222
Book Value per Share		 $2.81 $1.78 $1.05 $0.79 ($0.07) $1.41 $1.15 $1.08 $0.98 $2.30 $1.27
Tangible Book Value per Share		 $2.81 $1.78 $1.05 $0.79 ($0.07) $1.41 $1.15 $1.08 $0.98 $2.30 $1.27
Total Capital		 15 11 6.99 5.27 -0.39 95 86 80 73 173 168
Total Debt		 0.27 0.24 0.21 0.18 0.15 0.11 0.07 0.04 0.00 0.00 0.00
Total Long-Term Debt		 0.12 0.09 0.06 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -17 -13 -9.54 -7.76 -3.10 -97 -93 -88 -77 -179 -170
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.87 -2.33 -3.02 -2.89 -3.82 -2.72 -7.49 -7.63 -5.48 -6.96 -3.90
Debt-free Net Working Capital (DFNWC)		 15 11 6.73 5.05 -0.57 95 86 80 72 172 166
Net Working Capital (NWC)		 15 11 6.57 4.90 -0.72 95 86 80 72 172 166
Net Nonoperating Expense (NNE)		 1.26 1.10 1.30 1.42 1.70 3.08 3.46 2.33 2.99 3.09 3.89
Net Nonoperating Obligations (NNO)		 -17 -13 -9.54 -7.76 -3.10 -97 -93 -88 -77 -179 -170
Total Depreciation and Amortization (D&A)		 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 -1,249.55% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 9,975.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 9,876.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.86) ($0.69) ($0.73) ($0.66) ($0.65) ($0.51) ($0.15) ($0.11) ($0.13) ($0.10) ($0.10)
Adjusted Weighted Average Basic Shares Outstanding		 5.34M 6.03M 6.34M 7.54M 8.88M 23.71M 89.54M 90.01M 90.05M 98.31M 172.31M
Adjusted Diluted Earnings per Share		 ($0.86) ($0.69) ($0.73) ($0.66) ($0.65) ($0.51) ($0.15) ($0.11) ($0.13) ($0.10) ($0.10)
Adjusted Weighted Average Diluted Shares Outstanding		 5.34M 6.03M 6.34M 7.54M 8.88M 23.71M 89.54M 90.01M 90.05M 98.31M 172.31M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($0.69) $0.00 $0.00 $0.00 ($0.51) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 6.17M 6.48M 6.48M 7.46M 67.19M 74.34M 74.34M 74.52M 75.18M 132.03M 132.03M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.34 -3.08 -3.35 -3.54 -4.08 -9.05 -10 -7.58 -8.94 -9.64 -12
Normalized NOPAT Margin		 -4,195.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -5,773.14% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Inhibikase Therapeutics (NASDAQ: IKT) continues to operate like a development-stage biotech: no revenue, persistent losses, and heavy reliance on financing. The latest quarter shows meaningful cash usage in operations and investing, but the balance sheet remains very liquid, with a large cash-and-investments position that gives the company flexibility in the near term.

  • Cash and investments remain substantial. As of Q1 2026, IKT reported $170.4 million in cash and short-term investments, which is a strong liquidity cushion for a company still in clinical development.
  • No debt burden on the latest balance sheet. Short-term debt and total noncurrent liabilities were both $0 in Q1 2026, which reduces financial risk.
  • Equity financing has supported the balance sheet. The company raised $2.9 million from common equity in Q1 2026, adding to its cash position.
  • Working capital remains positive and large. Current assets of $172.2 million versus current liabilities of $5.7 million suggest a very strong near-term solvency position.
  • Expense discipline improved versus the prior year. Q1 2026 operating expenses of $17.8 million were lower than the company’s much larger quarterly spending later in 2025, though still elevated.
  • Revenue is still zero. IKT reported no sales in Q1 2026, so the company is still fully dependent on financing and/or future clinical success to create shareholder value.
  • R&D spending remains the core use of capital. Research and development expense was $10.8 million in Q1 2026, which is expected for a biotech but also highlights ongoing cash burn.
  • Shares outstanding have moved up over time. The weighted average basic share count rose sharply compared with early 2024, indicating dilution has been a recurring part of funding operations.
  • Operating losses remain substantial. Q1 2026 net loss was $16.4 million, and operating loss was $17.8 million, showing the business is still far from profitability.
  • Operating cash flow was negative. The company used $12.1 million in operations during Q1 2026, reinforcing that cash burn is ongoing.
  • Investing outflows were very large in the quarter. IKT used $80.5 million in investing activities in Q1 2026, mainly due to $90.6 million of investment purchases, which materially reduced cash despite some maturities.
  • Cash declined sharply from the prior quarter. Net change in cash and equivalents was negative $89.6 million in Q1 2026, a steep drop from the prior quarter’s cash-generating period.
  • Historically, the company has depended on large financing events to survive. In late 2025 and prior periods, equity issuance provided major cash inflows, indicating the business model is still highly dependent on capital markets.

Bottom line: IKT’s financial position is currently supported by a strong cash reserve and no debt, but the company still has no revenue and continues to burn cash. For retail investors, that means the story remains heavily tied to clinical progress and future financing needs rather than operating performance.

07/11/26 10:47 PM ETAI Generated. May Contain Errors.

Inhibikase Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Inhibikase Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Inhibikase Therapeutics' net income appears to be on an upward trend, with a most recent value of -$48.26 million in 2025, rising from -$2.85 million in 2020. The previous period was -$27.52 million in 2024. See Inhibikase Therapeutics' forecast for analyst expectations on what's next for the company.

Inhibikase Therapeutics' total operating income in 2025 was -$51.97 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $51.97 million

Over the last 5 years, Inhibikase Therapeutics' total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

Inhibikase Therapeutics' total liabilities were at $8.30 million at the end of 2025, a 122.3% increase from 2024, and a 66.1% increase since 2020.

In the past 5 years, Inhibikase Therapeutics' cash and equivalents has ranged from $7.19 million in 2022 to $139.22 million in 2025, and is currently $139.22 million as of their latest financial filing in 2025.

Over the last 5 years, Inhibikase Therapeutics' book value per share changed from 4.85 in 2020 to 2.30 in 2025, a change of -52.6%.


Related Companies

Financial statements for NASDAQ:IKT last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
Buy the “unseen winner of the AI race” before July 22
Marc Chaikin - the analyst who called Nvidia before a 45,000% surge - says one overlooked AI stock could split...
Chaikin Analytics | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely, LLC | Sponsoredtc pixel
Executive order could send gold to 6,000 per ounce
Executive Order 14330 will allow Americans to hold precious metals inside 401(k)s for the first time ever - an...
Cedar Gold Group | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Simple Options Trading For Beginners' book at no cost - normally $29.97. It ou...
Profits Run | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel